Contact Imprint Company: Corporate About HAL Allergies Products R&D Careers News About HAL Allergy Group State of the art in pharmaceutical development HAL Allergy Group (HAL Allergy) is a modern leader and innovator in the field of biopharmaceuticals and located at the Bio Science Park in Leiden, The Netherlands. Our focus since 1959 stems from the development, production and distribution of Allergen Immunotherapies for the treatment and prevention of allergic diseases. These immunotherapies are used primarily against common allergies such as hay fever, house dust mite allergy and allergic reactions towards wasp or bee stings. With offices in major European countries, HAL Allergy is one of the European top players, particularly in the field of allergy. We take more than a little pride in our international leading role in the production of allergen extracts, both for therapeutic and diagnostic purposes. In addition, we have an specific expertise in the area of contract manufacturing with focus on the production of biopharmaceutical products for preclinical and clinical studies. HAL Allergy originally stems from 'Haarlems Allergenen Laboratorium', a Dutch company set up in Haarlem. The company started as a small laboratory where, on request of several local general practitioners (GPs), extracts were prepared on a named patient basis to treat against allergic reactions. The core business of HAL Allergy was, and still is, the treatment of allergies with specific immunotherapies. Patients' well-being is always our top priority. From the beginning, HAL Allergy was located in the centre of Haarlem, The Netherlands. In the 1970's HAL Allergy grew to a mid-sized laboratory and expanded into the German market. Germany soon developed into a major export country for HAL Allergy products. Over the years the product portfolio has changed and developed along with its headquarters. In January 2007 HAL Allergy had to start looking for new bigger premises and chose to relocate to the Bio Science Park in Leiden, The Netherlands. Beside the development and production of allergy vaccines, HAL Allergy started a new business in 2012. This new Contract Manufacturing Organization (CMO), named HALIX, is engaged in the production of biotechnological products for preclinical and clinical studies. We employ around 300 highly specialized people across various functions. The departments at our headquarters include development, production, quality assurance and control, clinical and registration. Our staff works closely together with leading research institutes. At our locations in Germany, Poland, Austria, Spain and Italy we mainly focus on service and sales activities. Milestones of HAL Allergy 2016 Completion phase III study SUBLIVAC® Birch 2016 Completion First-in-Human study SCIT product for treatment of peanut allergy 2014 Introduction of PURETHAL® RUSH Scheme Birch 2012 Start HALIX Contract Manufacturing Organization 2011 Introduction of PURETHAL® RUSH Scheme Grasses 2009 Opening new GMP facilities in Leiden Introduction of SUBLIVAL FIX ® 2008 Introduction of PURETHAL® / SUBLIVAC® one bottle 2005 Start operations of HAL Allergy in Spain 2003 Start operations of HAL Allergy in Italy 2001 Start operations of HAL Allergy in Austria; Introduction of PURETHAL® Mites 2000 Start operations of HAL Allergy in Poland 1999 Extension of the PURETHAL® product range 1998 Introduction of VENOMENHAL® Bee and Wasp Venoms 1995 Introduction of SUBLIVAC® B.E.S.T. sublingual immunotherapy 1990 Introduction of PURETHAL® Birch and ACTI.TIP® system for type I-allergy 1988 Standardization of allergen extracts in Allergy Units (A.U.), according to the FDA standardization 1986 Introduction of Grasses (allergoid - glutaraldehyde modified depot extracts) 1982 HAL allergen extracts are stabilized by Epsilon Amino Caproic Acid (EACA) 1980 HALISA® - the HAL-ELISA for type III-allergy diagnosis - is introduced 1977 Introduction of product for the diagnosis of type III-allergies; Start operations of HAL Allergy in Germany 1974 Introduction of HAL® ORAL 1969 Introduction of aluminium hydroxide depot extracts 1966 Introduction of the first commercially available house-dust mite extract by HAL Introduction of the biological standardization for allergen activity determination for each batch 1965 Production of the first standard series of allergens for epicutaneous testing 1959 Foundation of HAL Allergy (Haarlems Allergenen Laboratorium BV) HAL Allergy is a subsidiary of the family owned Droege Group Droege Group (founded in 1988) is an independent advisory and investment company entirely family-owned. The company acts as a specialist for tailor-made transformation programs aiming to enhance corporate value. Droege Group combines its corporate family-run structure and capital strength into a family-equity business model. The group carries out direct investments with own equity in corporate subsidiaries and medium-sized companies in "special situations". With the guiding principle "Implementation - following all the rules of art," the group is a pioneer of implementation-oriented corporate development. Droege Group proves its implementation excellence daily within its own portfolio. The entrepreneurial platforms of the Droege Group are aligned to current megatrends (knowledge, connectivity, prevention, demography, shopping 4.0, future work). Enthusiasm for quality, innovation and speed determines the company's development. As a result the Droege Group has successfully positioned itself within the market, both nationally and internationally and operates in 30 countries. More information: www.droege-group.com HAL Allergy Group J.H. Oortweg 15-17 2333 CH Leiden The Netherlands Tel: +31 (88) 1959 000 Fax: +31 (88) 1959 001 e-Mail © HAL Allergy Group, 2017 ∙ All rights reserved About HAL Our Strategy Businesses International Production Responsibility Management Allergies Causes of Allergies Clinical Conditions Immune System Diagnosis Insights Products SCIT SLIT Diagnostic R&D Clinical Trials Product Pipeline Product Quality Scientific Advisory Board Careers Working at HAL Vacancies Process News Contact Imprint Terms of use Privacy Statement General Conditions